Figure 1. Mechanism of CAR-NK cell-mediated ADCC. Image Credit: Sino Biological Inc. Figure 1 depicts the concept of using CAR-NK cells in combination with antibody immunotherapy to counteract NK ...

“These data provide additional support for the use of AB-101 as a highly scaled, off-the-shelf, ADCC-enhancing NK cell product candidate with optimized cellular profile but without the need for ...

1,2 NK cells' anti-tumor activity is mediated by different mechanisms, including the antibody-dependent cellular cytotoxicity (ADCC ... the clinical efficacy of NK cell therapies and anti-tumor ...

We’ve also shown that CRISPR-mediated knockout of ADAM17, a suppressor of CD16 activity, can be used to further elevate ADCC, and to help maintain NK cell potency. These findings will be ...

Zalutumumab induced potent MNC-mediated ADCC via FcgRIII (CD16), which was poorly triggered by panitumumab. Interestingly, not only zalutumumab but also panitumumab recruited neutrophils for ADCC.

About AB-101 AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or ...

Artiva is testing the unmodified NK cell therapy in combination with anti-CD20 monoclonal antibody rituximab to assess its ability to enhance antibody-dependent cellular cytotoxicity (ADCC).